IL144583A0 - Chimeric protein kinase inhibitors - Google Patents

Chimeric protein kinase inhibitors

Info

Publication number
IL144583A0
IL144583A0 IL14458301A IL14458301A IL144583A0 IL 144583 A0 IL144583 A0 IL 144583A0 IL 14458301 A IL14458301 A IL 14458301A IL 14458301 A IL14458301 A IL 14458301A IL 144583 A0 IL144583 A0 IL 144583A0
Authority
IL
Israel
Prior art keywords
protein kinase
kinase inhibitors
chimeric protein
chimeric
inhibitors
Prior art date
Application number
IL14458301A
Other languages
English (en)
Original Assignee
Peptor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptor Ltd filed Critical Peptor Ltd
Priority to IL14458301A priority Critical patent/IL144583A0/xx
Publication of IL144583A0 publication Critical patent/IL144583A0/xx
Priority to JP2003515632A priority patent/JP2005501047A/ja
Priority to AU2002355204A priority patent/AU2002355204B2/en
Priority to EP02751604A priority patent/EP1416934A4/en
Priority to CA002455602A priority patent/CA2455602A1/en
Priority to NZ531120A priority patent/NZ531120A/en
Priority to PCT/IL2002/000618 priority patent/WO2003010281A2/en
Priority to US10/764,288 priority patent/US7407939B2/en
Priority to US11/862,542 priority patent/US20080070843A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL14458301A 2001-07-26 2001-07-26 Chimeric protein kinase inhibitors IL144583A0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IL14458301A IL144583A0 (en) 2001-07-26 2001-07-26 Chimeric protein kinase inhibitors
JP2003515632A JP2005501047A (ja) 2001-07-26 2002-07-25 ペプチド又はペプチド模倣物質と結合したatp模倣物質を含むプロテインキナーゼ阻害剤
AU2002355204A AU2002355204B2 (en) 2001-07-26 2002-07-25 Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or peptidomimetics
EP02751604A EP1416934A4 (en) 2001-07-26 2002-07-25 PROTEIN KINASE INHIBITORS WITH ATP MIMETICS, CONJUGATED TO PEPTIDES OR PEPTIDOMIMETICS
CA002455602A CA2455602A1 (en) 2001-07-26 2002-07-25 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics
NZ531120A NZ531120A (en) 2001-07-26 2002-07-25 Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or peptidomimetics
PCT/IL2002/000618 WO2003010281A2 (en) 2001-07-26 2002-07-25 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics
US10/764,288 US7407939B2 (en) 2001-07-26 2004-01-23 Protein kinase inhibitors comprising ATP mimetics conjugated to peptides or peptidomimetics
US11/862,542 US20080070843A1 (en) 2001-07-26 2007-09-27 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL14458301A IL144583A0 (en) 2001-07-26 2001-07-26 Chimeric protein kinase inhibitors

Publications (1)

Publication Number Publication Date
IL144583A0 true IL144583A0 (en) 2002-05-23

Family

ID=11075649

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14458301A IL144583A0 (en) 2001-07-26 2001-07-26 Chimeric protein kinase inhibitors

Country Status (8)

Country Link
US (2) US7407939B2 (ja)
EP (1) EP1416934A4 (ja)
JP (1) JP2005501047A (ja)
AU (1) AU2002355204B2 (ja)
CA (1) CA2455602A1 (ja)
IL (1) IL144583A0 (ja)
NZ (1) NZ531120A (ja)
WO (1) WO2003010281A2 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144583A0 (en) * 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
US20050004038A1 (en) * 2003-06-27 2005-01-06 Lyon Robert P. Bivalent inhibitors of Glutathione-S-Transferases
US8158586B2 (en) * 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
JP2009502983A (ja) * 2005-08-05 2009-01-29 ファーマギャップ インコーポレイテッド タンパク質キナーゼcイソフォームの抑制剤およびその使用
EE200600030A (et) * 2006-08-15 2008-04-15 Tartu �likool Proteiinkinaasi fluorestsents-sond
WO2008070823A2 (en) 2006-12-07 2008-06-12 University Of South Florida Substrate-mimetic akt inhibitor
US8431529B2 (en) * 2007-07-31 2013-04-30 Sanford-Burnham Medical Research Institute Bi-dentate compounds as kinase inhibitors
JP2012501654A (ja) * 2008-09-05 2012-01-26 アビラ セラピューティクス, インコーポレイテッド 不可逆的インヒビターの設計のためのアルゴリズム
TWI407972B (zh) * 2009-09-03 2013-09-11 Gradalis Inc 使用組織特異性擬肽配位體之標的遞送
CN102713618B (zh) * 2009-09-16 2015-07-15 新基阿维罗米克斯研究公司 蛋白激酶复合物和抑制剂
AU2010339456A1 (en) 2009-12-30 2012-07-05 Celgene Avilomics Research, Inc. Ligand-directed covalent modification of protein
US11162083B2 (en) 2018-06-14 2021-11-02 University Of South Carolina Peptide based inhibitors of Raf kinase protein dimerization and kinase activity
KR102152977B1 (ko) * 2018-08-29 2020-09-07 충남대학교 산학협력단 암 예방 또는 치료용 펩타이드 및 이를 포함하는 약학적 조성물
JP7385191B2 (ja) * 2019-08-30 2023-11-22 学校法人同志社 Eml4-alk阻害ペプチドおよびこれを含む肺がん治療薬

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69409641T2 (de) 1993-05-28 1998-11-26 Cephalon Inc Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
US5594090A (en) 1994-04-06 1997-01-14 Nof Corporation Alkylene sulfide group-containing prepolymer, polymerizable composition and optical material
US5475110A (en) 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5591855A (en) 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5650407A (en) 1995-04-05 1997-07-22 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
US20020065221A1 (en) * 1995-12-20 2002-05-30 Philip Cohen Control of protein synthesis, and screening method for agents
US20050053594A1 (en) * 1995-11-16 2005-03-10 Dario Alessi RAC-PK as a therapeutic agent or in diagnostics, screening method for agents and process for activating RAC-PK
AU1200497A (en) * 1995-12-20 1997-07-14 Medical Research Council Control of protein synthesis, and screening method for agents
SE9600769D0 (sv) * 1996-02-28 1996-02-28 Astra Ab Compounds useful as analgesic
US7037891B2 (en) * 1997-05-21 2006-05-02 Children's Medical Center Corporation Methods of modulating G-protein-coupled receptor kinase-associated signal transduction
US6174993B1 (en) * 1997-05-21 2001-01-16 The Children's Medical Center Corp. Short peptides which selectively modulate the activity of serine/threonine kinases
TR200000415T2 (tr) 1997-08-15 2000-08-21 Cephalon Inc. Prostat kanserinin tedavi edilmesi için birleşimler.
US6087350A (en) 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
WO2001070770A2 (en) 2000-03-21 2001-09-27 The Johns Hopkins University Bisubstrate inhibitors of kinases
IL152807A0 (en) * 2000-05-30 2003-06-24 Peptor Ltd Protein kinase inhibitors
AU2002252614B2 (en) * 2001-04-10 2006-09-14 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
IL144583A0 (en) 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
WO2003055506A1 (fr) * 2001-12-27 2003-07-10 Takeda Chemical Industries, Ltd. Medicaments pour la prevention et le traitement du cancer
EP1496981A2 (en) * 2002-04-08 2005-01-19 Merck & Co., Inc. Method of treating cancer
EP1578918A2 (en) 2002-04-23 2005-09-28 Duke University Atherosclerotic phenotype determinative genes and methods for using the same
IL156429A0 (en) 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases

Also Published As

Publication number Publication date
EP1416934A4 (en) 2005-11-02
EP1416934A2 (en) 2004-05-12
WO2003010281A2 (en) 2003-02-06
CA2455602A1 (en) 2003-02-06
WO2003010281A3 (en) 2003-11-13
US7407939B2 (en) 2008-08-05
NZ531120A (en) 2008-03-28
AU2002355204B8 (en) 2003-02-17
US20050026840A1 (en) 2005-02-03
US20080070843A1 (en) 2008-03-20
AU2002355204B2 (en) 2007-08-16
JP2005501047A (ja) 2005-01-13

Similar Documents

Publication Publication Date Title
HUP0400300A2 (en) Pyrrolopyrimidines as protein kinase inhibitors
HK1068134A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
HK1062433A1 (en) Pyrazole compounds useful as protein kinase inhibitors
HK1057543A1 (en) Pyrazole compounds useful as protein kinase inhibitors
IL161516A0 (en) Benzimidazoles useful as protein kinase inhibitors
IL144583A0 (en) Chimeric protein kinase inhibitors
SI1318997T1 (sl) Pirazolne spojine, uporabne kot inhibitorji protein-kinaze
IL145329A0 (en) Protein tyrosine kinase inhibitors
IL151779A0 (en) Protein tyrosine kinase inhibitors
SI1345922T1 (sl) Pirazolne spojine, koristne kot inhibitorji protein kinaze
AU2002355906A1 (en) Thiopyrane-4-ones as dna protein kinase inhibitors